Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C

Journal of Gastroenterology

Volumn 49, Issue 7, 2014, Pages 1152-1162

  Asahina, Yasuhiro ^a,b   Tsuchiya, Kaoru ^a   Nishimura, Takashi ^a,c   Muraoka, Masaru ^a,d   Suzuki, Yuichiro ^a,d   Tamaki, Nobuharu ^a   Yasui, Yutaka ^a   Hosokawa, Takanori ^a   Ueda, Ken ^a   Nakanishi, Hiroyuki ^a   Itakura, Jun ^a   Takahashi, Yuka ^a   Kurosaki, Masayuki ^a   Enomoto, Nobuyuki ^d   Nakagawa, Mina ^b   Kakinuma, Sei ^b   Watanabe, Mamoru ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Alanine aminotransferase; Fibrosis; Hepatocarcinogenesis; Interferon; Fetoprotein

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUTAMINE; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA; RIBAVIRIN; AFP PROTEIN, HUMAN; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC VARIABILITY; HEPATITIS C; HETEROZYGOTE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; AGED; COHORT ANALYSIS; COMPLICATION; DISEASE COURSE; DRUG COMBINATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HEPATITIS C, CHRONIC; LIVER TUMOR; METABOLISM; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN;

EID: 84905368327     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0858-2     Document Type: Article

References (17)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671-5. (Pubitemid 20349249)
2. Asahina Y, Tsuchiya K, Tamaki T, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52:518-27.
3. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. IFN therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174-81. (Pubitemid 29364999)
4. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. SVR to IFN-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-87. (Pubitemid 46453759)
5. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated IFN-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;10:1105-9.
6. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C IFN-alpha and ribavirin therapy. Nat Genet. 2009;10:1100-4.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
8. Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, et al. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013. doi:10.1002/hep.26442.
9. Asahina Y, Tsuchiya K, Muraoka M, Tanaka K, Suzuki Y, Tamaki N, et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology. 2012;55:20-9.
10. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513-20. (Pubitemid 24166476)
11. Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation. 2012;93:644-9.
12. Agúndez JA, García-Martin E, Maestro ML, Cuenca F, Martínez C, Ortega L, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS ONE. 2012;7:e37998.
13. Joshita S, Umemura T, Katsuyama Y, Ichikawa Y, Kimura T, Morita S, et al. Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection. Hum Immunol. 2012;73:298-300.
14. Osaki Y, Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, et al. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol. 2012;47:444-51.
15. Barreiro P, Pineda JA, Rallon N, Naggie S, Martín-Carbonero L, Neukam K, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis. 2011;203:1629-35.
16. Marabita F, Aghemo A, Nicola SD, Rumi MG, Cheroni C, Scavelli R, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011;54:1127-34.
17. Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, et al. IL28B alleles associated with poor HCV clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology. 2012;55:384-94.